2.50
Hdl Handle:
http://hdl.handle.net/10755/165196
Category:
Abstract
Type:
Presentation
Title:
ARSENIC - IT'S NOT JUST FOR KILLING RATS ANYMORE!
Author(s):
Carsello, Janice; Peoples, Lynda; Michael, Martha; Moore, Teresa; Trumbo, Karen; Hauer, Jennifer
Author Details:
Janice Carsello, RN BSN, Clinical Nurse III, Jefferson Home Infusion Service, Philadelphia, Pennsylvania, USA, email: nurscarp1@comcast.net; Lynda Peoples, RN, BSN; Martha Michael, RN, BSN; Teresa Moore, RN; Karen Trumbo, PharmD; Jennifer Hauer, PharmD
Abstract:
Approximately 10% of leukemias are diagnosed as Acute Promyelocytic Leukemia (APL). APL causes a rapid accumulation of abnormal white blood cells in bone marrow and blood, causing anemia, bleeding and susceptibility to infection. Arsenic compounds have been used medicinally for thousands of years. In the 1980's, Chinese researchers first used arsenic to treat leukemia, after finding that arsenic was an ingredient in several Chinese medicines. Jefferson Home Infusion Service (JHIS) has developed a plan of care to deliver this cutting edge therapy to patients in their homes. The purpose of developing this care plan for arsenic (Trisenox) administration was two fold. First, it enables our nurses to administer this potentially toxic medication to patients in their homes safely. Second, it allows the patient to receive the consolidation phase of their chemotherapy in the privacy of their own home. Induction therapy is administered in a hospital setting and should not exceed 60 doses. Patients are exposed to pathogens just by being hospitalized during this phase of treatment. There are also psychosocial issues related to the lengthy hospital stay necessary for completion of the induction therapy. Consolidation therapy is started 3 to 6 weeks after induction therapy is completed. JHIS provides patients with a safe alternative to being confined to the hospital or an outpatient infusion center during the consolidation phase of Trisenox therapy The patient continues to tolerate Trisenox at home, and has experienced no significant adverse reactions. Our experience in undertaking this innovative home infusion therapy bodes well for expanded use, suggests that, with judicious planning, Trisenox can be a safe and beneficial treatment at home New, innovative treatment strategies are always being developed to battle cancer. Nurses must be cognizant of the many issues surrounding their patients, not just which patient gets what drug. There are financial, psychosocial and quality of life issues that must be considered when a patient starts a drug treatment protocol. JHIS has enabled a patient population that would, just a few years ago, have been hospitalized for several months, to receive this cutting edge treatment while at home.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleARSENIC - IT'S NOT JUST FOR KILLING RATS ANYMORE!en_GB
dc.contributor.authorCarsello, Janiceen_US
dc.contributor.authorPeoples, Lyndaen_US
dc.contributor.authorMichael, Marthaen_US
dc.contributor.authorMoore, Teresaen_US
dc.contributor.authorTrumbo, Karenen_US
dc.contributor.authorHauer, Jenniferen_US
dc.author.detailsJanice Carsello, RN BSN, Clinical Nurse III, Jefferson Home Infusion Service, Philadelphia, Pennsylvania, USA, email: nurscarp1@comcast.net; Lynda Peoples, RN, BSN; Martha Michael, RN, BSN; Teresa Moore, RN; Karen Trumbo, PharmD; Jennifer Hauer, PharmDen_US
dc.identifier.urihttp://hdl.handle.net/10755/165196-
dc.description.abstractApproximately 10% of leukemias are diagnosed as Acute Promyelocytic Leukemia (APL). APL causes a rapid accumulation of abnormal white blood cells in bone marrow and blood, causing anemia, bleeding and susceptibility to infection. Arsenic compounds have been used medicinally for thousands of years. In the 1980's, Chinese researchers first used arsenic to treat leukemia, after finding that arsenic was an ingredient in several Chinese medicines. Jefferson Home Infusion Service (JHIS) has developed a plan of care to deliver this cutting edge therapy to patients in their homes. The purpose of developing this care plan for arsenic (Trisenox) administration was two fold. First, it enables our nurses to administer this potentially toxic medication to patients in their homes safely. Second, it allows the patient to receive the consolidation phase of their chemotherapy in the privacy of their own home. Induction therapy is administered in a hospital setting and should not exceed 60 doses. Patients are exposed to pathogens just by being hospitalized during this phase of treatment. There are also psychosocial issues related to the lengthy hospital stay necessary for completion of the induction therapy. Consolidation therapy is started 3 to 6 weeks after induction therapy is completed. JHIS provides patients with a safe alternative to being confined to the hospital or an outpatient infusion center during the consolidation phase of Trisenox therapy The patient continues to tolerate Trisenox at home, and has experienced no significant adverse reactions. Our experience in undertaking this innovative home infusion therapy bodes well for expanded use, suggests that, with judicious planning, Trisenox can be a safe and beneficial treatment at home New, innovative treatment strategies are always being developed to battle cancer. Nurses must be cognizant of the many issues surrounding their patients, not just which patient gets what drug. There are financial, psychosocial and quality of life issues that must be considered when a patient starts a drug treatment protocol. JHIS has enabled a patient population that would, just a few years ago, have been hospitalized for several months, to receive this cutting edge treatment while at home.en_GB
dc.date.available2011-10-27T12:14:13Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:14:13Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.